Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AstraZeneca PLC Regulatory Filings 2015

Apr 29, 2015

5229_ffr_2015-04-29_56546b9a-45ab-4f9e-a6cd-e870ab645d10.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of April 2015

Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_______

Transaction by Persons Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

The following individuals, who are all Directors of the Company, have notified us that they have purchased AstraZeneca PLC Ordinary Shares of $0.25 each or AstraZeneca American Depositary Shares (ADSs).

One AstraZeneca ADS equals one AstraZeneca PLC Ordinary Share of $0.25.

Name of Director Date of notification Date of purchase Number of shares purchased Purchase price
Bruce Burlington 28 April 2015 27 April 2015 600 $71.03
Graham Chipchase 28 April 2015 28 April 2015 1,100 4606p
Shriti Vadera 29 April 2015 29 April 2015 3,500 4563p

A C N Kemp

Company Secretary

29 April 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 29 April 2015
Name: Adrian Kemp
Title: Company Secretary